Sarab Alseoudi, MD
Neurology · Newton, KSNPI 1811956998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 1,413 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 9.3% — the pattern of someone who eats at a lot of different presentations. Among neurology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,413 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- EMD Serono, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Novartis$1K
- Biogen$1K
- AbbVie$1K
- plus $13K from 53 others
What the payments were for
- Consulting fees$1,4456%
- Speaking & faculty fees$1191%
- Food & beverage$20,79291%
- Education$4212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,777 in reported general payments places this provider in the 90th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $237,013 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $63,481 |
| EpidiolexCannabidiol (Cbd) | 16 | $48,552 |
| UbrelvyUbrogepant | 37 | $39,617 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $28,864 |
| Nurtec OdtRimegepant Sulfate | 23 | $26,389 |
| Tetrabenazine | 13 | $25,355 |
| XcopriCenobamate | 21 | $22,276 |
| BriviactBrivaracetam | 16 | $21,035 |
| NourianzIstradefylline | 11 | $20,416 |
| QuliptaAtogepant | 14 | $18,284 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $13,467 |
| Lacosamide | 33 | $12,485 |
| Clobazam | 22 | $8,372 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $994 | $237,01327 claims |
| CSL BehringPrivigen | $76 | $63,48116 claims |
| AbbVieUbrelvy, Qulipta | $1,169 | $57,90151 claims |
| PfizerNurtec Odt | $1,055 | $26,38923 claims |
| SK Life Science, Inc.Xcopri | $365 | $22,27621 claims |
| UCB, Inc.Briviact | $1,085 | $21,03516 claims |
| Kyowa Kirin, Inc.Nourianz | $202 | $20,41611 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $370 | $3,82349 claims |
| Upsher-smith Laboratories LLCTopiramate | $18 | $1,702196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 131 neurology providers in Kansas.
Other neurology in Newton
- Ivan OsorioKansas City$101.7M
- Jeffrey KaplanLenexa$1.9M
- Rajesh PahwaKansas City$889K
- Sheetal MalikTopeka$137K
- Richard DubinskyKansas City$122K
- Barbara Jean OttleyHays$116K
- Jeffrey BurnsKansas City$115K
- Douglas DavisSalina$100K
- Amanda ThuringerKansas City$87K
- Mamatha PasnoorKansas City$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.